Innovative Tools for Monitoring Antibody Degradation in Cancer Research

Cancer research has seen remarkable advancements over the years, particularly with the development of therapeutic antibodies. These innovations have transformed the landscape of targeted therapies, offering more precise and effective treatment options. Here, we discuss the Invitrogen™ LysoLight™ Antibody Labeling Kits designed to help further enhance the capabilities of cancer researchers.

The importance of therapeutic antibodies

The development of therapeutic antibodies began with the hybridoma technique introduced by Köhler and Milstein in 1975, which allowed for the large-scale production of monoclonal antibodies. This breakthrough paved the way for their use in therapy. The approval of the first therapeutic monoclonal antibody, Muromonab-CD3, was in 1986.  Later, Rituximab and Trastuzumab were approved in the late 1990s, marking significant milestones as these antibodies have remained central in antibody therapeutics.

Therapeutic antibodies work by targeting specific antigens on cancer cells, recruiting immune effector cells, or initiating complement pathways to destroy the cancer cells. This targeted approach, first envisioned by Paul Ehrlich in 1906, has evolved significantly due to advancements in antibody production and our understanding of antibody-antigen interactions.

The rise of antibody-drug conjugates

One of the most significant advancements in cancer therapy has been the development of Antibody-Drug Conjugates (ADCs). These conjugates combine the specificity of antibodies with the potency of cytotoxic drugs, increasing the therapeutic window while minimizing damage to healthy cells. ADCs deliver a toxic payload directly to cancer cells, which is then internalized and degraded within the lysosome, releasing the cytotoxic agent to kill the cell from within.

The need for advanced degradation detection

Despite the progress in ADC technology, there has been a need for tools to directly monitor the  degradation of target proteins. LysoLight Antibody Labeling Kits provide a direct method to assess protein degradation, which is crucial for confirming the efficacy of ADCs and other therapeutic antibodies.

How the Invitrogen LysoLight Antibody Labeling Kits work

The innovative probe in the LysoLight Antibody Labeling Kits is a functional molecule that binds to primary amines on the antibody surface. Initially non-fluorescent, it becomes fluorescent upon cleavage by lysosomal proteases like cathepsin B. This fluorescence indicates that the antibody has been internalized and degraded, helping to provide a clear, direct measure of degradation.

Illustration of LysoLight dye in action, demonstrating its specificity to the lysosome.

Enhancing cell imaging in cancer research with the Invitrogen™ EVOS™ M7000 Imaging System

The EVOS M7000 Imaging System, equipped with the EVOS Onstage Incubator, is an exceptional tool that enhances cancer research when used with LysoLight dyes. This imaging system allows for high-resolution, time-lapse imaging of live cells, providing real-time insights into cellular processes. Additionally, the EVOS Onstage Incubator maintains optimal conditions for cell health and viability, helping ensure that long-term imaging experiments can be conducted without compromising cell integrity.

When using LysoLight dyes, the EVOS M7000 Imaging System enables researchers to:

1. Monitor degradation in real-time: Observe the internalization and degradation of antibodies in live cells, providing immediate feedback on the efficacy of therapeutic antibodies.
2. Conduct long-term studies: The stability and non-toxicity of LysoLight dyes, combined with the Onstage Incubator, allow for extended imaging sessions, capturing crucial data over several hours or even days.
3. Enhance data accuracy: High-resolution imaging and precise environmental control help reduce variability and improve the reliability of data, facilitating more accurate conclusions.

Expanded options for antibody labeling

In addition to LysoLight dyes, various antibody labeling tools are available that incorporate both pH-insensitive and pH-sensitive dyes. The Invitrogen pHrodo dyes, for example, provide a positive indication of endocytosis by increasing fluorescence as the pH becomes more acidic. These dyes eliminate the need for wash steps and quencher dyes, making them highly efficient for monitoring antibody internalization and trafficking.

Conclusion

The LysoLight Antibody Labeling Kits, combined with the advanced capabilities of the EVOS M7000 Imaging System and complementary cell analysis reagents, represent a significant advancement in cancer research. By providing a direct measure of protein degradation and enabling real-time, long-term imaging, these tools help enhance researchers’ ability to develop and validate effective therapeutic antibodies. These innovations are poised to help accelerate cancer research and ultimately improve patient outcomes.

References

1. BioProbes Journal of Cell Biology Applications. (2017). Improved labeling tools for antibody–drug conjugate screening & characterization. BioProbes, 76.
2. Holly, R. (2024). Innovative tools for monitoring antibody degradation in cancer research [Webinar]. Thermo Fisher Scientific. Retrieved from here.

For Research Use Only. Not for use in diagnostic procedures.

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.